Rheumatology

Last updated: 3rd Sep 2024

Stay up to date in rheumatology: Guidelines, personalised pain management, expert discussions, and congress highlights.

Medical conditions

Close up of arthritic hands holding a green apple

Arthritis

Containing relevant Learning Zones, guidelines, trials and news.

Osteoarthritis

Containing relevant Learning Zones, guidelines, trials and news.

Lupus

Containing relevant Learning Zones, guidelines, trials and news.

Independent resources

Arthritis

Containing relevant Learning Zones, guidelines, trials and news.

Welcome:

Updates in your area
of interest

Articles your peers
are looking at

Bookmarks
saved

Days to your
next event

Related news and insights

Blue test tubes arranged in a line, disappearing into the background

Drug news

Dapirolizumab pegol phase III data presented at the American College of Rheumatology meeting shows significant reduction in systemic lupus erythematosus disease activity

UCB and Biogen Inc. presented detailed results from the Phase III PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE)

3 mins

Drug news

CHMP positive for Obodence ((denosumab biosimilar) to treat osteoporosis

Samsung Bioepis Co., Ltd. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion for two denosumab biosimilars – Obodence (60 mg pre-filled syringe) referencing Prolia (denosumab) and Xbryk (120mg vial) referencing Xgeva (denosumab) – also known as SB16

1 min

Drug news

GSK acquires from Chimagen Biosciences CMG 1A46 a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE)

GSK plc and Chimagen Biosciences Chengdu Chimagen Biosciences Co Lt), a privately held biotechnology company, announced an agreement for GSK to acquire CMG 1A46, a clinical-stage dual CD19 and CD20-targeted T cell-engager (TCE), from Chimagen for $300 million upfront. GSK plans to develop and commercialise CMG 1A46 with a focus on B cell-driven autoimmune diseases, such as systemic lupus erythematosus (SLE) and lupus nephritis (LN), with potential to expand into related autoimmune diseases.

1 min

See all news